Investment Thesis
Pulmatrix is a pre-revenue biotech company with minimal revenue generation ($53K) despite near-term cash burn of $5.8M quarterly (negative free cash flow). With only $4.1M in cash on hand, the company has less than one year of operational runway at current burn rates, creating existential risk absent significant external financing or transformative clinical/commercial milestones.
Strengths
- Zero long-term debt with clean balance sheet
- Strong liquidity position with 12.55x current ratio
- Net loss improvement of 46% YoY indicates some operational progress
Risks
- Unsustainable quarterly cash burn of -$5.8M against $4.1M total cash reserves (sub-12 month runway)
- Operating margin of -9752% with minimal revenue generation signals no clear path to profitability
- No insider buying activity in 90 days; typical of distressed biotech situations
- Revenue base of $53K is immaterial and does not support operating expenses
Key Metrics to Watch
- Cash burn rate and duration of cash runway before financing need
- Revenue growth trajectory and evidence of commercial traction or partnering
- Clinical trial progress and pipeline advancement as potential catalysts
Financial Metrics
Revenue
53.0K
Net Income
-5.2M
EPS (Diluted)
$-1.41
Free Cash Flow
-5.8M
Total Assets
4.1M
Cash
4.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-9,752.8%
Net Margin
-9,739.6%
ROE
-135.5%
ROA
-124.7%
FCF Margin
-11,001.9%
Balance Sheet & Liquidity
Current Ratio
12.55x
Quick Ratio
12.55x
Debt/Equity
0.00x
Debt/Assets
7.9%
Interest Coverage
-27.79x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T18:51:21.400215 |
Data as of: 2025-12-31 |
Powered by Claude AI